3,4-disubstituted 1h-pyrazole compounds and their use as cyclin dependent kinase and glycogen synthase kinase-3 modulators

A method for treatment of a disease state or condition mediated by a cyclin dependent kinase (CDK) or glycogen synthase kinase-3, which method comprises administering to a mammal in need thereof a compound of the formula (II):

• or a salt, or tautomer, N-oxide, or solvate thereof;
• wherein
• Y is a bond or an alkylene chain of 1, 2 or 3 carbon atoms in length;
• R1 is a carbocyclic or heterocyclic group having from 3 to 12 ring members, wherein the carbocyclic or heterocyclic group is unsubstituted or substituted by one or more substituent groups R10;
• or a C1-8 hydrocarbyl group optionally substituted by one or more substituents selected from fluorine, hydroxy, C1-4 hydrocarbyloxy, amino, mono- or di-C1-4 hydrocarbylamino, and carbocyclic or heterocyclic groups having from 3 to 12 ring members wherein the carbocyclic or heterocyclic groups are unsubstituted or substituted by one or more substituent groups R10;
• R2 is hydrogen or methyl;
• R3 is selected from non-aromatic carbocyclic and heterocyclic groups having from 3 to 12 ring members, wherein the carbocyclic or heterocyclic groups are unsubstituted or substituted by one or more substituent groups R10;
• and
• R10 is selected from halogen, hydroxy, trifluoromethyl, cyano, nitro, carboxy, amino, mono- or di-C1-4 hydrocarbylamino, carbocyclic and heterocyclic groups having from 3 to 12 ring members;
• a group Ra-Rb wherein Ra is a bond, O, CO, X1C(X2), C(X2)X1, X1C(X2)X1, S, SO, SO2, NRc, SO2NRc or NRcSO2;
• and Rb is selected from hydrogen, carbocyclic and heterocyclic groups having from 3 to 12 ring members, and a C1-8 hydrocarbyl group optionally substituted by one or more substituents selected from hydroxy, oxo, halogen, cyano, nitro, carboxy, amino, mono- or di-C1-4 hydrocarbylamino, carbocyclic and heterocyclic groups having from 3 to 12 ring members;
• Rc is selected from hydrogen and C1-4 hydrocarbyl;
• and
• X1 is O, S or NRc and X2 is ═O, ═S or ═NRc;
• and provided that where the substituent group R10 comprises or includes a carbocyclic or heterocyclic group, the said carbocyclic or heterocyclic group may be unsubstituted or may itself be substituted with one or more further substituent groups R10 and wherein (a) such further substituent groups R10 include carbocyclic or heterocyclic groups, which are not themselves further substituted;
• or (b) the said further substituents do not include carbocyclic or heterocyclic groups but are otherwise selected from the groups listed above in the definition of R10.